BLFS vs. OM, VRAY, ZYXI, EDAP, AXGN, LIVN, TMDX, ITGR, INMD, and CNMD
Should you be buying BioLife Solutions stock or one of its competitors? The main competitors of BioLife Solutions include Outset Medical (OM), ViewRay (VRAY), Zynex (ZYXI), Edap Tms (EDAP), AxoGen (AXGN), LivaNova (LIVN), TransMedics Group (TMDX), Integer (ITGR), InMode (INMD), and CONMED (CNMD). These companies are all part of the "electromedical equipment" industry.
BioLife Solutions vs.
Outset Medical (NASDAQ:OM) and BioLife Solutions (NASDAQ:BLFS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability, valuation and community ranking.
Outset Medical has a beta of 1.56, indicating that its stock price is 56% more volatile than the S&P 500. Comparatively, BioLife Solutions has a beta of 1.86, indicating that its stock price is 86% more volatile than the S&P 500.
BioLife Solutions received 280 more outperform votes than Outset Medical when rated by MarketBeat users. Likewise, 67.96% of users gave BioLife Solutions an outperform vote while only 37.78% of users gave Outset Medical an outperform vote.
98.8% of Outset Medical shares are owned by institutional investors. Comparatively, 89.8% of BioLife Solutions shares are owned by institutional investors. 4.0% of Outset Medical shares are owned by company insiders. Comparatively, 3.3% of BioLife Solutions shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
BioLife Solutions has a net margin of -85.79% compared to Outset Medical's net margin of -141.24%. BioLife Solutions' return on equity of -6.79% beat Outset Medical's return on equity.
Outset Medical currently has a consensus price target of $24.50, suggesting a potential upside of 28.21%. BioLife Solutions has a consensus price target of $30.00, suggesting a potential upside of 39.34%. Given BioLife Solutions' stronger consensus rating and higher probable upside, analysts plainly believe BioLife Solutions is more favorable than Outset Medical.
In the previous week, BioLife Solutions had 5 more articles in the media than Outset Medical. MarketBeat recorded 8 mentions for BioLife Solutions and 3 mentions for Outset Medical. BioLife Solutions' average media sentiment score of 0.21 beat Outset Medical's score of -0.09 indicating that BioLife Solutions is being referred to more favorably in the news media.
BioLife Solutions has higher revenue and earnings than Outset Medical. BioLife Solutions is trading at a lower price-to-earnings ratio than Outset Medical, indicating that it is currently the more affordable of the two stocks.
Summary
BioLife Solutions beats Outset Medical on 13 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BLFS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioLife Solutions Competitors List
